Description : CYRAMZA (ramucirumab), a prescription drug, is a recombinant human IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor 2. CYRAMZA is a sterile, preservative-free, intravenous infusion following dilution and preparation.
CYRAMZA is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-dose vials. CYRAMZA is formulated in glycine (9.98 mg/mL), histidine (0.65 mg/mL), histidine monohydrochloride (1.22 mg/mL), polysorbate 80 (0.1 mg/mL), sodium chloride (4.383 mg/mL), and Water for Injection, USP, pH 6.0.
Manufacturer : Eli Lilly and Company
Strengths available : 100 mg/10 mL & 500 mg/50 mL
Form : Vials
Drug Type : Anti Cancer
Storage : Store vials in a refrigerator at 2°C to 8°C. DO NOT FREEZE OR SHAKE the vial.
FDA Approval : US FDA Approved
Date of Approval : April 21st, 2014
Gastric Cancer :
The recommended dose of CYRAMZA either as a single agent or in combination with weekly paclitaxel is 8 mg/kg every 2 weeks administered as an intravenous infusion over 60 minutes. Continue CYRAMZA until disease progression or unacceptable toxicity.
When given in combination, administer CYRAMZA prior to administration of paclitaxel.
Non-Small Cell Lung Cancer :
The recommended dose of CYRAMZA is 10 mg/kg administered by intravenous infusion over 60 minutes on day 1 of a 21-day cycle prior to docetaxel infusion. Continue CYRAMZA until disease progression or unacceptable toxicity.
Colorectal Cancer :
The recommended dose of CYRAMZA is 8 mg/kg every 2 weeks administered by intravenous infusion over 60 minutes prior to FOLFIRI administration. Continue CYRAMZA until disease progression or unacceptable toxicity.
Common and serious side effects may be Hemorrhage, Arterial Thromboembolic Events, Hypertension, Infusion-Related Reactions, Gastrointestinal Perforation, Impaired Wound Healing, Patients with Child-Pugh B or C Cirrhosis, Reversible Posterior Leukoencephalopathy Syndrome, Proteinuria Including Nephrotic Syndrome, Thyroid